Basic Actigall Information

• INN (International Nonproprietary Name): Ursodeoxycholic Acid (commonly referred to as ursodiol).
• Brand Names Available In Canada (English): Actigall — Capsules 300 mg (bottle counts vary).
• ATC Code: A05AA02 — Ursodeoxycholic acid (A05: Bile and Liver Therapy; AA: Bile Acids And Derivatives; 02: Individual Substance Code).
• Forms & Dosages: Capsules 300 mg (most common), Tablets 250 mg and 500 mg.
• Manufacturers In Canada (English): Not specified.
• Registration Status In Canada (English): Authorized As Prescription-Only (Rx).
• OTC / Rx Classification: Prescription-Only (Rx) In Major Markets Including Canada.

Key Findings From Recent Trials

Concerned about whether Actigall still works for bile disease and gallstones?

Recent Canadian and international studies from 2022–2025 confirm consistent trends for ursodiol in clinical practice.

Ursodeoxycholic acid retains first-line status for primary biliary cholangitis with reliable improvements in cholestatic markers such as alkaline phosphatase.

Canadian cohort and multicentre observational data align with EMA and FDA registries showing sustained biochemical response in roughly 40–60% of treated PBC patients on standard UDCA dosing.

Meta-analyses highlight heterogeneity in secondary endpoints, but reductions in alkaline phosphatase are a consistent primary outcome across studies.

For gallstones, low-to-moderate evidence supports prophylactic UDCA to reduce gallstone formation after rapid weight loss, notably in bariatric surgery cohorts.

Small, non-calcified cholesterol stones show partial radiologic dissolution with months of therapy when using recommended dosing bands.

Common search terms patients use include actigall, ursodiol, and Actigall 300 mg when comparing options and outcomes.

Main Outcomes

What improvements should patients expect?

Primary outcomes reported are improved liver biochemistry for PBC patients, especially reductions in alkaline phosphatase and bilirubin trends when applicable.

For gallstone therapy, trials report partial radiologic dissolution of small, non-calcified cholesterol stones over 6–24 months of treatment.

Typical daily dosing used in these studies ranged from 8–15 mg/kg/day depending on indication and patient weight.

Imaging follow-up and serial liver function tests are routine endpoints used to confirm response in both clinical trials and practice.

Safety Observations

Is ursodiol safe based on recent data?

Post-market surveillance from 2022–2025 reports primarily gastrointestinal adverse events such as diarrhoea and nausea, along with occasional rash and rare hypersensitivity.

No new class-wide safety signals were identified during that period in Canadian or international datasets.

Serious allergic reactions remain very rare, and most events are mild to moderate and manageable with counselling or dose adjustments.

Common terms patients search include ursodiol safety and Actigall 300 mg adverse events when reviewing tolerability.

Clinical Mechanism Of Action

How does Actigall work in plain language?

Ursodeoxycholic acid is a hydrophilic bile acid that replaces more toxic endogenous bile acids and improves bile flow.

That change reduces cholesterol saturation in bile, which allows small cholesterol stones to dissolve slowly over months in suitable patients.

In primary biliary cholangitis, UDCA reduces cholestasis and helps limit immune-mediated bile duct injury, improving liver enzyme patterns and slowing disease progression.

Scientific Breakdown

What happens at the cellular and hepatic level?

UDCA reduces hepatic bile acid toxicity and promotes choleresis, the process of bile secretion from hepatocytes into bile canaliculi.

The drug stabilizes hepatocyte membranes and alters enterohepatic circulation of bile acids, shifting the bile acid pool toward less cytotoxic species.

Molecular Effects

At the molecular level, UDCA upregulates hepatocanalicular transporters and downregulates pro-apoptotic signalling pathways.

It competes with hydrophobic bile acids, reducing cytotoxicity and oxidative stress in hepatocytes and cholangiocytes.

Pharmacokinetics (Concise)

UDCA is orally absorbed and undergoes hepatic conjugation and enterohepatic recirculation.

Typical Canadian formulations include Actigall 300 mg capsules and tablet generics available in 250 mg and 500 mg strengths.

When counselling, pharmacists often explain that steady-state effects take weeks to months, especially for gallstone dissolution.

Scope Of Approved & Off-Label Use

Which uses are Health Canada–approved and what do clinicians try off-label?

Health Canada authorizes ursodiol as a prescription-only medicine with DIN-assigned products that include branded Actigall 300 mg and generics.

Approved indications include dissolution of non-calcified cholesterol gallstones in suitable patients and treatment of primary biliary cholangitis at weight-based dosing.

These monograph indications align with the ATC classification A05AA02 for bile acids and derivatives.

Notable Off-Label Trends In Canadian Practice

What do hepatologists and bariatric teams commonly use UDCA for beyond labels?

Off-label uses observed in Canadian clinics include prophylaxis of gallstones during rapid weight loss after bariatric surgery using short-term 300 mg twice daily regimens.

Adjunctive use for other cholestatic liver conditions appears in specialist practice, while paediatric use under 18 years remains limited due to sparse data.

Pharmacists field questions about ursodiol prescription and Urso tablet availability from patients considering bariatric surgery.

Provincial Reimbursement Context

How do provincial plans handle coverage?

Coverage varies by provincial plans such as Ontario Drug Benefit, BC PharmaCare, and RAMQ, and often requires special authorisation for chronic PBC therapy.

Pharmacy teams frequently assist with paperwork for long-term listings and authorisation criteria to reduce out-of-pocket costs for patients.

Dosage Strategy

How is dosing chosen for different indications?

Standard adult dosing for gallstone dissolution is approximately 8–10 mg/kg/day, which for many average-weight adults translates to 300 mg twice daily.

For primary biliary cholangitis the recommended dosing is higher at 13–15 mg/kg/day, divided across the day.

Actigall is commonly dispensed in 300 mg capsules in Canada, and tablets in 250 mg or 500 mg strengths are used when appropriate.

Condition-Specific Dosing Adjustments

How long should a patient expect to take treatment for gallstones or PBC?

Gallstone therapy usually continues for 6–24 months with ultrasound monitoring every 3–6 months to confirm dissolution.

Bariatric prophylaxis regimens in trials used empiric 300 mg twice daily during rapid weight-loss phases to lower gallstone formation risk.

PBC patients typically remain on lifelong UDCA therapy with periodic biochemical monitoring and dose titration by weight and response.

Special Populations

Elderly patients do not require routine dose reductions unless hepatic or renal dysfunction is present, and monitoring is advised.

Children under 18 have limited evidence for most indications, so use is uncommon and specialist-guided.

UDCA is contraindicated in decompensated liver disease or complete biliary obstruction and requires LFT monitoring if hepatic impairment exists.

Safety Protocols

Who should not take Actigall?

Absolute contraindications per Canadian and international labelling include complete biliary obstruction, known hypersensitivity to ursodiol, and chronic calcified gallstones where the drug is ineffective.

Initiation should be avoided during acute cholecystitis or biliary tract infection until the acute issue is managed.

Adverse Effects (Post-Market Reports)

What side effects do people report in Canada?

Most frequent adverse effects are diarrhoea, nausea, abdominal pain, and occasional rash, with moderate reports of headache and back pain.

Severe allergic reactions are very rare, and Health Canada surveillance through 2022–2025 did not uncover new systemic safety signals.

Patients should contact a clinician if they develop worsening abdominal pain, jaundice, or signs of allergic reaction.

Monitoring And Escalation

What monitoring is recommended?

Baseline and periodic liver function tests are recommended, especially for PBC patients, and imaging for gallstones should be scheduled as advised.

Discontinue UDCA if clinical deterioration of liver function or signs of biliary obstruction occur and consult a specialist for further management.

Pregnancy and breastfeeding require individualized risk–benefit discussions with an obstetrician or hepatologist.

Interaction Mapping

Can food or other drugs change how UDCA works?

There are no major food–drug interactions commonly reported for UDCA, but absorption and bile dynamics may be modestly influenced by high-fat meals.

Patients who experience gastrointestinal upset are usually advised to take the dose with food to improve tolerance.

Drug Combinations Flagged By Health Canada

Which drugs need a timing adjustment or monitoring?

Bile acid sequestrants like cholestyramine can reduce UDCA absorption, so separating dosing by several hours is recommended.

Caution is advised when combining UDCA with drugs affecting hepatic transporters or bile flow, and clinicians monitor closely if combining with hepatotoxic agents or obeticholic acid used in PBC.

Pharmacists often flag recent starts of antibiotics, cholestatic drugs, or new hepatotoxic agents in provincial medication records.

Practical Pharmacy Flags

What should community pharmacists document and counsel?

Document recent medication changes, advise separation from bile acid sequestrants, encourage scheduled LFT monitoring, and counsel on missed-dose guidance.

Pharmacies such as Shoppers Drug Mart, Rexall, London Drugs, and Jean Coutu will note DINs and special authorisation needs when dispensing UDCA.

Patient Experience Analysis

What do Canadian patients report about Actigall and ursodiol?

Provincial surveys and clinic feedback from 2022–2025 show that most PBC patients notice biochemical improvement and some symptom relief, though pruritus response is variable.

Patients undergoing gallstone dissolution often describe slow timelines, repeated imaging, and occasional discontinuation because of persistent diarrhoea.

Common patient questions centre on Actigall availability, out-of-pocket costs, and bilingual labelling for medication leaflets.

Forum & Community Pharmacy Trends

What topics show up in forums and at the counter?

Community pharmacies regularly field queries about generic ursodiol tablets versus Actigall 300 mg, coverage under provincial plans, and cross-border pricing discussions.

Pharmacists frequently counsel on missed doses, storage below 25°C, and when to seek urgent care for signs of obstruction.

Accessibility & Adherence Issues

Why do some patients stop therapy prematurely?

Adherence is affected by prolonged treatment durations, intermittent diarrhoea, and provincial coverage inconsistencies that require special authorisation for chronic PBC therapy.

Pharmacy support with paperwork, patient education, and counselling often improves persistence with therapy.

Distribution & Pricing Landscape

Where do Canadians get Actigall and how much might it cost?

Actigall 300 mg and ursodiol generics are dispensed through major Canadian chains such as Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs, subject to depot stocking and provincial formularies.

Online Canadian pharmacies list Actigall and generics by prescription, and provincial regulations and PharmaCare rules determine coverage and cost to the patient.

Online Pharmacy Availability & Provincial Restrictions

Can patients order online and will provincial coverage apply?

Online Canadian pharmacies require a valid prescription and may assist with special-authorisation submissions for provincial plans such as Ontario Drug Benefit, BC PharmaCare, and RAMQ.

Costs vary by plan and patient eligibility, and many patients compare generics and bottle sizes to manage out-of-pocket expenses.

Cross-Border US Comparisons

Is it cheaper to buy UDCA from the United States?

US pricing for Actigall 300 mg can be lower in some cases, prompting cross-border interest, but importation rules and prescription validity limit routine personal importation.

Bulk generics from India or the EU affect global pricing, while Canadian DIN and bilingual labelling standards influence supply chain choices and availability.

In our online pharmacy, actigall is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Alternative Options

What other treatments are available for gallstones or PBC?

DIN-approved options in Canada mainly include ursodiol generics and Actigall, while alternatives for gallstones or cholestasis include chenodiol in some markets and surgical cholecystectomy.

For primary biliary cholangitis, obeticholic acid is an adjunctive therapy prescribed by specialists for UDCA nonresponders.

Pros And Cons Checklist

• Ursodiol (Actigall): Pros — proven biochemical benefit in PBC, oral, generally well tolerated; Cons — slow effect for gallstones, ineffective for calcified stones.
• Obeticholic Acid: Pros — option for UDCA-nonresponders; Cons — cost, specialist prescribing, and pruritus risk.
• Chenodiol: Pros — potential gallstone dissolution in some patients; Cons — higher hepatotoxicity risk and limited availability in Canada.

Regulatory Status

How is ursodiol regulated in Canada?

Ursodeoxycholic acid products are approved through Health Canada’s standard review pathway and are marketed with DINs that specify indications, dosing, and safety data consistent with FDA and EMA labels.

PBC indications follow labelled authorisations and provincial formularies may treat chronic PBC listings with additional evidence requirements.

DIN And Bilingual Labelling Rules

What must appear on the product and how is dispensing controlled?

All marketed UDCA products in Canada carry a Drug Identification Number and must include English/French bilingual labelling and patient medication information as required by Health Canada.

Pharmacies must comply with provincial dispensing regulations and provide the patient with the mandated bilingual leaflet at the point of sale.

Post-Market Obligations

What do manufacturers and pharmacies need to report?

Manufacturers are required to report adverse events to Health Canada, and provincial formularies may require additional data or special authorisation paperwork for listing decisions.

Community pharmacies document adverse events and assist patients with coverage claims and special authorisations as part of routine care.

Consolidated FAQ

Q1: Is Actigall available in Canada without a prescription?

A1: No — Actigall and ursodiol generics are prescription-only products with DIN oversight in Canada.

Q2: How long to see results dissolving gallstones?

A2: Expect 6–24 months of therapy with periodic ultrasound to confirm dissolution, applicable to small non-calcified cholesterol stones.

Q3: Will UDCA help with weight loss or indigestion?

A3: No — UDCA is not indicated for weight loss or general dyspepsia.

Q4: Does provincial drug coverage pay for Actigall?

A4: Coverage varies; PBC often qualifies under provincial special authorisation programs such as Ontario Drug Benefit, BC PharmaCare, and RAMQ; check with local pharmacy or insurer.

Q5: Can I take Actigall during pregnancy?

A5: Use only if a clinician determines the expected benefit outweighs potential risks; consult an obstetrician or hepatologist.

Visual Guide

What visuals help clinicians and patients understand UDCA use?

Recommended infographics include dosage visuals showing weight-based dosing bands for gallstones (8–10 mg/kg) versus PBC (13–15 mg/kg) with example tablet and capsule counts like Actigall 300 mg and Urso 250/500 mg.

A provincial coverage map highlighting Ontario Drug Benefit, BC PharmaCare, and RAMQ special-authorisation pathways is helpful for patient navigation.

A purchase channels flowchart distinguishing community chains (Shoppers, Rexall, Jean Coutu, London Drugs) from accredited online pharmacies clarifies prescription-only status and import limitations.

A monitoring timeline graphic should show baseline liver function tests, imaging schedule for gallstones (every 3–6 months), and chronic PBC surveillance cadence.

Design notes: use bilingual (EN/FR) labels, DIN and brand examples, storage icons for <25°C, and accessible colour contrast for patient materials.

Storage & Transport

How should patients and pharmacies store Actigall?

Store ursodiol below 25°C (77°F) and protect it from moisture and heat.

Do not freeze the product and keep it in the original container, ideally with any child-resistant cap provided.

Pharmacists commonly advise against bathroom storage and recommend a cool, dry place away from direct sunlight.

Cold-Chain Storage Where Applicable

Does UDCA require cold-chain handling?

UDCA products do not require refrigeration and standard ambient supply chain storage is sufficient.

However, extreme winter temperatures during cross-border shipping or deliveries to remote Northern communities may require insulated packaging to prevent freezing.

Pharmacy Logistics

What should pharmacies document during stocking and delivery?

Document storage conditions for bulk stock and ensure DIN-labelled products include bilingual patient leaflets on dispensing.

For mail-order prescriptions confirm courier handling and use protective packaging to avoid exposure to excessive heat or cold during transit.

Guidelines For Proper Use

What practical points should pharmacists emphasise during counselling?

Counsel patients to take UDCA exactly as prescribed and to keep scheduled liver function tests and imaging appointments.

Advise taking the medication with food if gastrointestinal upset occurs and to separate bile-acid sequestrants by several hours.

Document provincial coverage details and assist with special-authorisation paperwork when chronic therapy is needed.

Provincial Health Authority Guidance

When should clinicians refer to specialists?

Provincial hepatology guidelines reflected in ODB and PharmaCare criteria recommend weight-based dosing, periodic monitoring, and specialist referral for PBC or nonresponders to UDCA.

Surgical referral remains indicated for symptomatic or complicated gallstone disease despite medical therapy.

Practical Checklist For Patients

• Verify prescription and DIN at the pharmacy.
• Confirm provincial coverage or special-authorisation status before long-term therapy.
• Obtain baseline LFTs and imaging ordered by the prescriber.
• Expect months of therapy for gallstone dissolution and carry the bilingual medication leaflet.
• Keep follow-up appointments and report new abdominal pain or jaundice promptly.

Delivery Across Canada (English)

Concluding Notes For Patients And Clinicians

Choosing the right treatment depends on stone type, disease indication, and patient preferences.

Actigall and ursodiol generics are effective options for non-calcified cholesterol gallstones and remain first-line medical therapy for primary biliary cholangitis when prescribed at appropriate weight-based doses.

Pharmacists should verify DINs, counsel on adverse effects such as diarrhoea, and arrange monitoring with the prescriber.

Patients should expect gradual improvement over months and maintain scheduled imaging and LFT checks to assess response.

For benefit–risk discussions in pregnancy, advanced liver disease, or combined therapies such as obeticholic acid, specialist consultation is recommended.

If cost or coverage is a barrier, ask the dispensing pharmacy about special authorisation pathways under Ontario Drug Benefit, BC PharmaCare, or RAMQ and about generic ursodiol options.